Ginsenoside Re (Synonyms: Chikusetsusaponin IVc, NSC 308877, Panaxoside Re, Sanchinoside Re) |
Catalog No.GN10307
One-Click Copy Product Info
|
Ginsenoside Re is a natural compound found in Panax ginseng, possessing potent antioxidant and anti-inflammatory bioactivities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 52286-59-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ginsenoside Re is a natural compound found in Panax ginseng, possessing potent antioxidant and anti-inflammatory bioactivities[1]. Ginsenoside Re is commonly used in the treatment of cardiovascular diseases (myocardial ischemia, arrhythmia), and is also extensively studied for neuroprotection in Alzheimer's/Parkinson's disease, improvement of metabolic function (diabetes), and promotion of bone regeneration[2,3,4].
In vitro, pretreatment of primary dopaminergic midbrain neurons with Ginsenoside Re (1, 5, 10μM) for 2h, followed by exposure to CCl4 (2.5mM) for 48h, significantly reduced CCl4-induced loss of tyrosine hydroxylase (TH+) positive neurons and preserved neurite length and number[5]. Pretreatment of PC12 cells with Ginsenoside Re (0.1-100μM) for 2h, followed by incubation in serum-free medium for 24-96h, markedly attenuated serum deprivation-induced cytotoxicity and enhanced cell viability[6].
In vivo, administration of Ginsenoside Re (10mg/kg/day) via intraperitoneal injection to ob/ob mice for 12 days resulted in a 17.8% reduction in the area under the curve (AUC) for glucose during an intraperitoneal glucose tolerance test (IPGTT) and significantly improved glucose diposal[7]. Intragastrically of Ginsenoside Re (15mg/kg) to mice for 7 consecutive days, followed by intraperitoneal injection of lipopolysaccharide (LPS; 10mg/kg), significantly increased 24-hour survival rates and prolonged survival time[8].
References:
[1] HUANG Y C, CHEN C T, CHEN S C, et al. A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration[J]. Pharmaceutical Research, 2005, 22(4): 636-646.
[2] KIM J H, YI Y S, KIM M Y, et al. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases[J]. Journal of Ginseng Research, 2017, 41(4): 435-443.
[3] KIM J H. Pharmacological and medical applications of Panax ginseng and ginsenosides: a review for use in cardiovascular diseases[J]. Journal of Ginseng Research, 2018, 42(3): 264-269.
[4] WANG Y, ZHANG G, DENG L, et al. Ginsenoside Re promotes osteogenic differentiation via BMP2/p38 pathway in vivo and in vitro[J]. Journal of Ginseng Research, 2025.
[5] ZHANG X, WANG Y, MA C, et al. Ginsenoside Rd and ginsenoside Re offer neuroprotection in a novel model of Parkinson’s disease[J]. American Journal of Neurodegenerative Disease, 2016, 5(1): 52.
[6] JI Z N, DONG T T X, YE W C, et al. Ginsenoside Re attenuate β-amyloid and serum-free induced neurotoxicity in PC12 cells[J]. Journal of Ethnopharmacology, 2006, 107(1): 48-52.
[7] XIE J T, MEHENDALE S R, LI X, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2005, 1740(3): 319-325.
[8] CHEN R C, WANG J, YANG L, et al. Protective effects of ginsenoside Re on lipopolysaccharide-induced cardiac dysfunction in mice[J]. Food & Function, 2016, 7(5): 2278-2287.
| Cell experiment [1]: | |
Cell lines | Primary dopaminergic midbrain neuron |
Preparation Method | Primary dopaminergic midbrain neuron were pretreated with 1, 5, and 10μM Ginsenoside Re for 2h and then exposed to 2.5mM CCl4 for 48h. TH+ positive neurons were identified by immunocytochemical staining, and their neurite length, and neurite number were assessed under microscopy. |
Reaction Conditions | 1, 5, and 10μM; 2h |
Applications | Ginsenoside Re treatment significantly reduced CCl4-induced loss of TH+ positive neurons and protected neurite length and number. |
| Animal experiment [2]: | |
Animal models | C57BL/6J ob/ob mice |
Preparation Method | ob/ob mice were administered Ginsenoside Re (10mg/kg) via daily intraperitoneal injection for 12 consecutive days, followed by an intraperitoneal glucose tolerance test (IPGTT) in which glucose (2g/kg) was injected intraperitoneally and blood glucose levels were measured from the tail vein at 0, 30, 60, and 120min. Glucose exposure was evaluated by calculating the AUC for glucose. |
Dosage form | 10mg/kg/day; 12 days; i.p. |
Applications | Treatment with Ginsenoside Re reduced the AUC for glucose by 17.8% compared to the control group, and significantly improved glucose disposal. |
References: | |
| Cas No. | 52286-59-6 | SDF | |
| Synonyms | Chikusetsusaponin IVc, NSC 308877, Panaxoside Re, Sanchinoside Re | ||
| Chemical Name | Panaxoside RE, Ginsenoside B2, Chikusetsusaponin IVc | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O | ||
| Formula | C48H82O18 | M.Wt | 947.14 |
| Solubility | ≥ 43.1mg/mL in DMSO | Storage | Store at 2-8°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0558 mL | 5.2791 mL | 10.5581 mL |
| 5 mM | 211.2 μL | 1.0558 mL | 2.1116 mL |
| 10 mM | 105.6 μL | 527.9 μL | 1.0558 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)